T
Toregem BioPharma
Tooth regeneration medicine from Kyoto University — grow teeth with an injection
About Toregem BioPharma
Toregem BioPharma Co., Ltd. is a Kyoto University venture founded in May 2020 to research, develop, and commercialize tooth regeneration medicine based on the work of CTO Katsu Takahashi. The company is developing a neutralizing antibody approach that suppresses molecules inhibiting tooth-bud growth, aiming for the world's first injectable medicine that grows a patient's own teeth. Near-term focus is congenital edentulism; longer term the company targets tooth loss from decay and periodontal disease to extend healthy lifespan through retained natural dentition. Headquarters: Kamigyo-ku, Kyoto, Japan. Official site: https://toregem.co.jp/en/
Source: Dealroom company dataNews
Open roles
Toregem BioPharma in the Kyoto ecosystem
The Toregem BioPharma office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed2 investors entered at this stage
Kyoto University Innovation CapitalKyogin Lease & Capital
Series A14 investors entered at this stage
Astellas Venture
Future Venture Capital- KCKyoshin Social Capital
Gemseki- STSanyo Trading
Tohoku University Venture Partners
Taisho Pharmaceutical
JIC Venture Growth Investments
Mitsubishi UFJ Capital- GCGreen Core
SIIF Impact Capital
Osaka University Venture Capital
Shofu- CCChushin Venture Capital
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Toregem BioPharma on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Toregem BioPharma on the full Dealroom platform
Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.

